The global Platelet Rich Plasma (PRP) market is experiencing robust expansion, with a market size of USD 519.5 million in 2021, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 14.8 percent during the forecast period. The widespread adoption of platelet-rich plasma across various medical fields, including orthopedic disorders, cardiovascular and neurovascular diseases, general surgery, wound management, and aesthetic procedures, is fueling this growth. Additionally, the market benefits from the increasing aging population and the growing acceptance of PRP as an effective treatment option.
Diverse Applications Driving Market Growth
The platelet-rich plasma market has witnessed sustained growth due to its numerous applications. Cosmetic procedures, in particular, have seen a surge in demand, with over 18.1 million cosmetic procedures performed in the United States in 2019, according to the American Society of Plastic Surgeons. Procedures like facelifts and liposuction have gained popularity, contributing to the markets growth. PRPs expanding applications in areas such as anti-aging treatments, hair loss, skin rejuvenation, and the treatment of various injuries, including tendon, ligament, muscle, and joint injuries, have significantly contributed to its market expansion.
High Incidence of Androgenetic Alopecia and Rising Musculoskeletal Disorders
The market is further driven by the high incidence of androgenetic alopecia (AGA) and the increasing prevalence of musculoskeletal disorders worldwide. AGA, a form of hormone-related baldness, affects millions of individuals, making PRP an attractive treatment option. In the United States alone, over 50% of males over the age of 50 experience some degree of hair loss, with AGA often starting in a persons teen years. Musculoskeletal disorders, including osteoarthritis, have also fueled the demand for PRP therapy. PRP has shown promise in inhibiting inflammation, stimulating cartilage formation, and reducing joint pain, making it an effective treatment for osteoarthritis.
COVID-19 Impact and Recovery
The COVID-19 pandemic had a temporary impact on the PRP market, with the suspension of elective cosmetic procedures to prioritize the treatment of COVID-19 patients. However, as of January 2021, the market had stabilized, and supply and demand returned to normal. The research into COVID-19 treatments and vaccine development also contributed to a slower growth rate in the PRP market during the pandemic.
Challenges Ahead: High Treatment Costs
Despite its growth, the PRP market faces challenges, primarily related to the high cost of therapy. PRP treatment costs can range from $500 to $2,500 per session, and in some cases, multiple sessions may be required. The cost varies based on the provider, location, facilities, and the expertise of the treating physician. Additionally, insurance coverage for PRP treatment is not guaranteed, limiting its accessibility.
Segment Analysis: Pure Platelet-Rich Plasma Dominates
In terms of types, pure platelet-rich plasma holds the highest revenue share due to its broad applications in tissue repair, regeneration, and healing processes. While leukocyte-rich platelet-rich plasma is gaining traction, particularly in orthopedics and sports injuries, pure PRP remains the dominant segment.
Hospitals Lead in End-Use Segment
Among end-use categories, hospitals lead the market, driven by the increasing adoption of PRP-based therapies for osteoarthritis and hair loss. Hospitals are equipped with the necessary infrastructure and equipment to administer PRP treatments effectively.
Regional Landscape: North America Takes the Lead
North America is expected to dominate the market throughout the forecast period, with the United States witnessing a rising prevalence of diseases such as arthritis. According to the Centers for Disease Control and Prevention (CDC), one in four individuals in the United States had arthritis in 2020, with an estimated 78 million adults expected to suffer from the condition by 2040. This, coupled with an aging population, supports the markets growth.
The European market is anticipated to experience stable growth, with a focus on research and development in platelet-rich plasma applications, especially in the field of sports-related injuries and healthcare.
Competitive Landscape
Several key players in the Platelet Rich Plasma market include Johnson & Johnson, Arthrex, Inc., EmCyte Corporation, DR. PRP AMERICA, LLC, Juventix, Terumo Corporation, Zimmer Biomet, Stryker, Apex Biologix, and Celling Biosciences. These companies are actively engaged in strategic partnerships and acquisitions to expand their product offerings and strengthen their market position.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/platelet-rich-plasma-market
Visit Our Trending Blogs:
https://hackmd.io/@MnywLZx1RpmWcgPTqNwHtQ/BkKcayAE6
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: [email protected]
This press release first seen on Brilad
COMTEX_444219541/2840/2023-11-30T00:36:55
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Sahyadri Times journalist was involved in the writing and production of this article.
